Zomedica (ZOM) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Atmosphere Carbon Circular Climate Climate Change Emission Energy Efficiency Environment Forest Fossil Fuel Greenhouse Gas Emission Life Cycle Materials Nature Nuclear Offset Packaging Pandemic Pollution Raw Materials Resiliency Water Wind Access Attrition Benefits Black Collective Bargaining Community Culture Customer Cyber Cyber Security Cybersecurity Data Security Death Disability Employee Employee Retention Engagement Gender Health and Safety Health Care Healthcare Hire Hiring Human Capital Human Resources Incident Injuries Recall Recruit Reimbursement Retention Retirement Safety Satisfaction Skill Skilled Skills Social Society Supplier Supply Chain Training Union Women Workforce Anti-corruption Assessment Assurance Audit Bonus Chronic Classified Commitment Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Independent Chair Innovation Innovative Key Performance Indicator Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Purpose R&D Recoup Reputation Research and Development Responsibility Responsible Shareholder Proposals Special Meeting Strategy Sustainable Targets Tax Tenure Term Limit Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 7, 2022, Zomedica Corp. (the “Corporation”) held its Annual Virtual-Only Meeting of the holders (the “Shareholders”) of common shares (“Common Shares”) of the Corporation (the “Annual Meeting”). The matters voted on at the Annual Meeting were: (i) the election of directors of the Corporation, (ii) the appointment of Grant Thornton LLP as the Corporation’s auditors, (iii) the approval of, on an advisory basis, the executive compensation of the Corporation’s named executive officers and (iv) the approval of, on an advisory basis, how often the Corporation will conduct an advisory vote on executive compensation. Shareholders representing 294,570,954 shares, or 30.1%, of the Common Shares outstanding as of the April 18, 2022 record date were represented at the Annual Meeting in person or by proxy. The proposals are described in detail in the Corporation’s definitive proxy statement for the Annual Meeting (described as the Management Information Circular and Proxy Statement) filed with the Securities and Exchange Commission on April 26, 2022. The final voting results were as provided below. For purposes of providing percentage information below, any Common Shares that were the subject of abstentions or broker non-votes have been ignored in accordance with Canadian law. Therefore, the percentages reflected in relation to proposals 1 and 2 reflect only votes “for” or “withheld,” the percentages reflected in relation to proposal 3 reflect only votes “for” or “against,” and the percentages reflected in relation to proposal 4 reflect only votes for “1 Year,” “2 Years,” or “3 Years.”

1. The Shareholders elected the following nominees, Jeffrey Rowe, Robert Cohen, Chris MacLeod, Johnny D. Powers, Sean Whelan and Rodney Williams, as directors of the Corporation to serve until the Corporation’s 2023 annual meeting of shareholders or until their successors are elected or appointed.

	FOR	PERCENTAGE FOR	WITHHELD	PERCENTAGE WITHHELD	BROKER NON-VOTES
Jeffrey Rowe	104,104,495	87.4%	14,955,347	12.6%	175,511,112
Robert Cohen	105,517,119	88.6%	13,542,722	11.4%	175,511,113
Chris MacLeod	107,407,443	90.2%	11,652,399	9.8%	175,511,112
Johnny D. Powers	102,408,141	86.0%	16,651,701	14.0%	175,511,112
Sean Whelan	109,739,741	92.2%	9,320,101	7.8%	175,511,112
Rodney Williams	85,023,543	71.4%	34,036,299	28.6%	175,511,112

2.The proposal to appoint Grant Thornton LLP as the Corporation’s auditors until the Corporation’s 2023 annual meeting of shareholders was approved by the Shareholders based upon the following votes:

FOR		PERCENTAGE FOR		WITHHELD		PERCENTAGE WITHHELD		BROKER NON-VOTES
286,830,884		97.4%		7,740,070		2.6%		0

3.The proposal to approve, on an advisory basis, the executive compensation of the Corporation’s named executive officers was approved by the Shareholders based upon the following votes:

FOR		PERCENTAGE FOR		AGAINST		PERCENTAGE AGAINST		ABSTAIN		BROKER NON-VOTES
93,518,593		80.3%		22,982,259		19.7%		2,558,991		175,511,111

4. The Shareholders approved, on an advisory basis, every one year as the frequency for future advisory votes on named executive officer compensation. In light of such approval, the Corporation intends to hold an advisory vote on the compensation of the Corporation’s named executive officers on an annual basis until the next required vote on the frequency of holding an advisory vote to approve named executive officer compensation. The tabulation of votes with respect to this proposal was as follows:

1 YEAR		PERCENTAGE 1 YEAR		2 YEARS		PERCENTAGE 2 YEARS		3 YEARS		PERCENTAGE 3 YEARS		ABSTAIN		BROKER NON-VOTES
97,896,372		84.9%		8,050,072		7.0%		9,379,669		8.1%		3,733,730		175,511,111